Protein Microarrays for Personalized Medicine

Abstract Background: Over the last 10 years, DNA microarrays have achieved a robust analytical performance, enabling their use for analyzing the whole transcriptome or for screening thousands of single-nucleotide polymorphisms in a single experiment. DNA microarrays allow scientists to correlate gene expression signatures with disease progression, to screen for disease-specific mutations, and to treat patients according to their individual genetic profiles; however, the real key is proteins and their manifold functions. It is necessary to achieve a greater understanding of not only protein function and abundance but also their role in the development of diseases. Protein concentrations have been shown to reflect the physiological and pathologic state of an organ, tissue, or cells far more directly than DNA, and proteins can be profiled effectively with protein microarrays, which require only a small amount of sample material. Content: Protein microarrays have become well-established tools in basic and applied research, and the first products have already entered the in vitro diagnostics market. This review focuses on protein microarray applications for biomarker discovery and validation, disease diagnosis, and use within the area of personalized medicine. Summary: Protein microarrays have proved to be reliable research tools in screening for a multitude of parameters with only a minimal quantity of sample and have enormous potential in applications for diagnostic and personalized medicine.

[1]  Pil Je Park,et al.  The multiplex bead array approach to identifying serum biomarkers associated with breast cancer , 2009, Breast Cancer Research.

[2]  Dieter Stoll,et al.  Protein microarrays for diagnostic assays , 2009, Analytical and bioanalytical chemistry.

[3]  J. Daurès,et al.  Protein biochip array technology to monitor rituximab in rheumatoid arthritis , 2009, Clinical and experimental immunology.

[4]  Jinghua Zhao,et al.  Development and Preliminary Evaluation of a Multivariate Index Assay for Ovarian Cancer , 2009, PloS one.

[5]  Thomas M Braun,et al.  A biomarker panel for acute graft-versus-host disease. , 2009, Blood.

[6]  M. Duffy,et al.  A personalized approach to cancer treatment: how biomarkers can help. , 2008, Clinical chemistry.

[7]  I. Cho,et al.  Cytokine Profiling of Prostatic Fluid From Cancerous Prostate Glands Identifies Cytokines Associated with Extent of Tumor and Inflammation , 2008 .

[8]  R. Ferris,et al.  Multiplex analysis of cytokines as biomarkers that differentiate benign and malignant thyroid diseases , 2008, Proteomics. Clinical applications.

[9]  P. Szurman,et al.  Vitreous levels of bevacizumab and vascular endothelial growth factor-A in patients with choroidal neovascularization. , 2008, Ophthalmology.

[10]  Sarah L. Keasey,et al.  Analysis of the human immune response to vaccinia by use of a novel protein microarray suggests that antibodies recognize less than 10% of the total viral proteome , 2008, Proteomics. Clinical applications.

[11]  Wesley S Wiggins,et al.  Multianalyte Profiling of Serum Antigens and Autoimmune and Infectious Disease Molecules to Identify Biomarkers Dysregulated in Epithelial Ovarian Cancer , 2008, Cancer Epidemiology Biomarkers & Prevention.

[12]  Sanjeeva Srivastava,et al.  Applications of protein microarrays for biomarker discovery , 2008, Proteomics. Clinical applications.

[13]  Emanuel F. Petricoin,et al.  Laser Capture Microdissection and Protein Microarray Analysis of Human Non-small Cell Lung Cancer , 2008, Molecular & Cellular Proteomics.

[14]  E. Canet,et al.  L’Initiative Médicaments Innovants - Développement de l’innovation biomédicale en Europe , 2008 .

[15]  A. Verstraete.  HANDBOOK OF DRUG MONITORING METHODS, THERAPEUTICS AND DRUGS OF ABUSE , 2008 .

[16]  K. Margolin.  Cytokine therapy in cancer , 2008, Expert opinion on biological therapy.

[17]  N. Dossat,et al.  Protein biochip array technology for cytokine profiling predicts etanercept responsiveness in rheumatoid arthritis , 2008, Clinical and experimental immunology.

[18]  L. Liotta,et al.  National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for use of tumor markers in clinical practice: quality requirements. , 2008, Clinical chemistry.

[19]  W. Isaacs,et al.  Cytokine profiling of prostatic fluid from cancerous prostate glands identifies cytokines associated with extent of tumor and inflammation , 2008, The Prostate.

[20]  Rainer Muche,et al.  Prediction of Nodal Involvement in Breast Cancer Based on Multiparametric Protein Analyses from Preoperative Core Needle Biopsies of the Primary Lesion , 2008, Clinical Cancer Research.

[21]  Carsten Peterson,et al.  Detection of pancreatic cancer using antibody microarray‐based serum protein profiling , 2008, Proteomics.

[22]  Yanhui Hu,et al.  Next generation high density self assembling functional protein arrays , 2008, Nature Methods.

[23]  J. O’Shea,et al.  Cytokine signaling modules in inflammatory responses. , 2008, Immunity.

[24]  R. Bernards,et al.  Enabling personalized cancer medicine through analysis of gene-expression patterns , 2008, Nature.

[25]  P. Treuting,et al.  Serum biomarkers in a mouse model of bacterial‐induced inflammatory bowel disease , 2008, Inflammatory bowel diseases.

[26]  Dina Aronzon,et al.  Application of protein microarrays for multiplexed detection of antibodies to tumor antigens in breast cancer. , 2008, Journal of proteome research.

[27]  D. Ward,et al.  Diagnostic Markers for Early Detection of Ovarian Cancer , 2008, Clinical Cancer Research.

[28]  Mariaelena Pierobon,et al.  Multiplexed cell signaling analysis of human breast cancer applications for personalized therapy. , 2008, Journal of proteome research.

[29]  Mårten Fernö,et al.  Serum proteome profiling of metastatic breast cancer using recombinant antibody microarrays. , 2008, European journal of cancer.

[30]  Thomas Joos,et al.  New frontiers in microarray technology development. , 2008, Current opinion in biotechnology.

[31]  Y. L. Ramachandra,et al.  Human Proteinpedia enables sharing of human protein data , 2008, Nature Biotechnology.

[32]  Janet Woodcock,et al.  The FDA critical path initiative and its influence on new drug development. , 2008, Annual review of medicine.

[33]  Gabriel S. Eichler,et al.  Signal pathway profiling of epithelial and stromal compartments of colonic carcinoma reveals epithelial-mesenchymal transition , 2008, Oncogene.

[34]  G. Zhou,et al.  Protein Expression Profiling of Breast Cancer Cells by Dissociable Antibody Microarray (DAMA) Staining*S , 2008, Molecular & Cellular Proteomics.

[35]  Gil Mor,et al.  Identification of differentially expressed proteins in ovarian cancer using high-density protein microarrays , 2007, Proceedings of the National Academy of Sciences.

[36]  Xuewu Zhang,et al.  Biomarker validation: movement towards personalized medicine , 2007, Expert review of molecular diagnostics.

[37]  Harvey B Pollard,et al.  Protein microarray platforms for clinical proteomics , 2007, Proteomics. Clinical applications.

[38]  Emanuel F Petricoin,et al.  A systems biology approach to the pathogenesis of obesity‐related nonalcoholic fatty liver disease using reverse phase protein microarrays for multiplexed cell signaling analysis , 2007, Hepatology.

[39]  M. Caron,et al.  Cancer Immunomics Using Autoantibody Signatures for Biomarker Discovery* , 2007, Molecular & Cellular Proteomics.

[40]  G. MacBeath,et al.  An integrated approach to prognosis using protein microarrays and nonparametric methods , 2007, Molecular systems biology.

[41]  P. Albert,et al.  Nuclear Factor-κB–Related Serum Factors as Longitudinal Biomarkers of Response and Survival in Advanced Oropharyngeal Carcinoma , 2007, Clinical Cancer Research.

[42]  Fernando A Bozza,et al.  Cytokine profiles as markers of disease severity in sepsis: a multiplex analysis , 2007, Critical care.

[43]  Gabriel S. Eichler,et al.  Phosphoprotein pathway mapping: Akt/mammalian target of rapamycin activation is negatively associated with childhood rhabdomyosarcoma survival. , 2007, Cancer research.

[44]  Ruo-Pan Huang,et al.  An array of possibilities in cancer research using cytokine antibody arrays , 2007, Expert review of proteomics.

[45]  C. Salustri,et al.  Ceruloplasmin (2-D PAGE) Pattern and Copper Content in Serum and Brain of Alzheimer Disease Patients , 2007 .

[46]  T. Joos,et al.  The long and difficult road to the diagnostic market: protein microarrays. , 2006, Drug discovery today.

[47]  M. Snyder,et al.  Protein microarray technology , 2006, Mechanisms of Ageing and Development.

[48]  Stephen R Master,et al.  Diagnostic challenges for multiplexed protein microarrays. , 2006, Drug discovery today.

[49]  John G. Albeck,et al.  Collecting and organizing systematic sets of protein data , 2006, Nature Reviews Molecular Cell Biology.

[50]  Larry J Kricka,et al.  Current perspectives in protein array technology , 2006, Annals of clinical biochemistry.

[51]  Xiaobo Yu,et al.  Label‐free detection methods for protein microarrays , 2006, Proteomics.

[52]  Steven A Carr,et al.  Protein biomarker discovery and validation: the long and uncertain path to clinical utility , 2006, Nature Biotechnology.

[53]  C. Gulmann,et al.  Array‐based proteomics: mapping of protein circuitries for diagnostics, prognostics, and therapy guidance in cancer , 2006, The Journal of pathology.

[54]  S. Kingsmore.  Multiplexed protein measurement: technologies and applications of protein and antibody arrays , 2006, Nature Reviews Drug Discovery.

[55]  Shaohui Hu,et al.  Severe acute respiratory syndrome diagnostics using a coronavirus protein microarray. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[56]  D. Daly,et al.  ELISA microarray technology as a high-throughput system for cancer biomarker validation , 2006, Expert review of proteomics.

[57]  Xiaobo Yu,et al.  Label-free electrochemical detection for aptamer-based array electrodes. , 2005, Analytical chemistry.

[58]  Joshua LaBaer,et al.  So, you want to look for biomarkers (introduction to the special biomarkers issue). , 2005, Journal of proteome research.

[59]  Joshua LaBaer,et al.  The sentinel within: exploiting the immune system for cancer biomarkers. , 2005, Journal of proteome research.

[60]  Leroy Hood,et al.  Systems biology, proteomics, and the future of health care: toward predictive, preventative, and personalized medicine. , 2004, Journal of proteome research.

[61]  M. A. Bopp,et al.  Zeptosens' protein microarrays: A novel high performance microarray platform for low abundance protein analysis , 2002, Proteomics.

[62]  Mariaelena Pierobon,et al.  Reverse-phase protein microarrays. , 2012, Methods in molecular biology.

[63]  S. Servoss,et al.  High-throughput analysis of serum antigens using sandwich ELISAs on microarrays. , 2009, Methods in molecular biology.

[64]  Xiaobo Yu,et al.  Protein microarrays: effective tools for the study of inflammatory diseases. , 2009, Methods in molecular biology.

[65]  E. Petricoin,et al.  Reverse-phase protein microarrays for theranostics and patient tailored therapy. , 2009, Methods in molecular biology.

[66]  Stephen R Master,et al.  Validation and Quality Control of Protein Microarray-based Analytical Methods , 2008, Molecular biotechnology.

[67]  E. Canet,et al.  [The Innovative Medicine Initiative (IMI)]. , 2008, Medecine sciences : M/S.

[68]  E. Petricoin,et al.  Molecular network analysis using reverse phase protein microarrays for patient tailored therapy. , 2008, Advances in experimental medicine and biology.

[69]  E. Petricoin,et al.  Putting the "bio" back into biomarkers: orienting proteomic discovery toward biology and away from the measurement platform. , 2008, Clinical chemistry.

[70]  Steven H. Y. Wong,et al.  Pharmacogenomics and Personalized Medicine , 2008, Methods in Pharmacology and Toxicology.

[71]  A. Dasgupta.  Handbook of drug monitoring methods; therapeutics and drugs of abuse. , 2008 .

[72]  E. Petricoin,et al.  Reverse phase protein microarrays for theranostics and patient-tailored therapy. , 2008, Methods in molecular biology.

[73]  David E. Gloriam,et al.  ProteomeBinders: planning a European resource of affinity reagents for analysis of the human proteome , 2007, Nature Methods.

[74]  John G Doench,et al.  Screens using RNAi and cDNA expression as surrogates for genetics in mammalian tissue culture cells. , 2005, Cold Spring Harbor symposia on quantitative biology.

[75]  Geoffrey S. Ginsburg,et al.  The Personalized Medicine Coalition , 2005, American journal of pharmacogenomics : genomics-related research in drug development and clinical practice.